Increased plasma conc w/ protease (eg, ritonavir, saquinavir) & CYP3A4 (eg, ketoconazole, erythromycin, clarithromycin, itraconazole) inhibitors, grapefruit juice. Potential drug interactions mediated by transport inhibitors. Decreased plasma conc w/ CYP3A4 inducers eg, rifampicin, phenobarb, phenytoin, carbamazepine. Augmented hypotensive effects of nitrates. Increased BP-lowering effect of doxazosin. Augmented hypotensive effects w/ riociguat. Increased oral bioavailability of ethinylestradiol, terbutaline. Concomitant use w/ α-blockers, 5α-reductase inhibitors, CYP1A2 substrates eg, theophylline.